Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.

[1]  J. Pouchot,et al.  Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) , 2023, Oncoimmunology.

[2]  G. Otterson,et al.  Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis , 2023, Cancer Immunology, Immunotherapy.

[3]  D. McDonnell,et al.  Eosinophilia in cancer and its regulation by sex hormones , 2022, Trends in Endocrinology & Metabolism.

[4]  Xiaoye Zhang,et al.  Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review , 2022, Frontiers in Oncology.

[5]  Yilang Wang,et al.  Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB , 2022, Disease markers.

[6]  J. Alcaraz,et al.  Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play , 2022, International journal of molecular sciences.

[7]  Qiqing Huang,et al.  Interleukin-19 Aggravates Pulmonary Fibrosis via Activating Fibroblast through TGF-β/Smad Pathway , 2022, Mediators of inflammation.

[8]  Paulo Luiz Carvalho Francescantônio,et al.  How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative , 2021, Immunologic Research.

[9]  P. Libby,et al.  Interleukins in cancer: from biology to therapy , 2021, Nature Reviews Cancer.

[10]  J. Cortijo,et al.  Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms , 2021, International journal of molecular sciences.

[11]  T. Schwartz,et al.  Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. , 2021, Chest.

[12]  D. Hamann,et al.  Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review , 2021, Frontiers in Oncology.

[13]  K. Azuma,et al.  Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy , 2021, Investigational New Drugs.

[14]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2020, Pharmacology & therapeutics.

[15]  H. Chiba,et al.  CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features , 2020, PloS one.

[16]  H. Ohdan,et al.  Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers , 2020, JAMA network open.

[17]  T. Wynn,et al.  Fibrosis: from mechanisms to medicines , 2020, Nature.

[18]  W. Liang,et al.  Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials , 2020, Cancer.

[19]  D. Ettinger,et al.  Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. , 2020, JAMA oncology.

[20]  Y. Nishioka,et al.  Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study , 2020, Scientific Reports.

[21]  D. Lynch,et al.  Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. , 2020, The Lancet. Respiratory medicine.

[22]  N. Inui,et al.  Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[24]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[25]  T. Kondo,et al.  Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor , 2018, International journal of cancer.

[26]  Y. Ohe,et al.  Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. , 2018, Lung cancer.

[27]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[28]  Giuseppe Curigliano,et al.  Targeting the microenvironment in solid tumors. , 2018, Cancer treatment reviews.

[29]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[30]  C. Langer,et al.  Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , 2017, Lung cancer.

[31]  A. Giobbie-Hurder,et al.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[32]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[33]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[34]  F. Hodi,et al.  PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course , 2016, Clinical Cancer Research.

[35]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[36]  Sheng-ping Li,et al.  Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma , 2016, Oncotarget.

[37]  P. Jänne,et al.  Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer , 2016, Cancer Immunology Research.

[38]  C. Owen,et al.  Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. , 2015, American journal of respiratory cell and molecular biology.

[39]  F. Hodi,et al.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.

[40]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[41]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[42]  S. Rutz,et al.  The IL-20 subfamily of cytokines — from host defence to tissue homeostasis , 2014, Nature Reviews Immunology.

[43]  M. Kanazawa,et al.  Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. , 2014, Respiratory investigation.

[44]  Chien-Feng Li,et al.  Interleukin-19 in Breast Cancer , 2013, Clinical & developmental immunology.

[45]  Rafael Sirera,et al.  The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  Hélène Dumortier,et al.  CXCR3, Inflammation, and Autoimmune Diseases , 2009, Annals of the New York Academy of Sciences.

[47]  W. Parks,et al.  Control of matrix metalloproteinase catalytic activity. , 2007, Matrix biology : journal of the International Society for Matrix Biology.